Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Efalizumab for Treatment of Patients With Moderate to Severe Psoriasis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00442650
Recruitment Status : Completed
First Posted : March 2, 2007
Last Update Posted : November 21, 2016
Information provided by:
Merck KGaA, Darmstadt, Germany

Brief Summary:
Multicentre, open label, phase III study. Subjects with moderate to severe psoriasis were given efalizumab subcutaneously once per week for the 12-week treatment period. Assessments involved physical examination, disease activity assessments, clinical laboratory tests (haematology, blood chemistry and standard urinalysis), evaluation of the Psoriasis Area and Severity Index (PASI), the Physician's Global Assessment (PGA), the Patient's Global Psoriasis Assessment (PGPA), the SF-36 Health Survey and psoriatic body surface area (BSA). The 12-week treatment period was followed by a 12-week follow-up (FU) period, during which other antipsoriatic medications were allowed. The same assessments were also performed in the 12-week FU period.

Condition or disease Intervention/treatment Phase
Moderate to Severe Psoriasis Drug: Efalizumab Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Study Start Date : January 2004
Actual Primary Completion Date : December 2005
Actual Study Completion Date : December 2005

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Psoriasis

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All

Inclusion Criteria:

  1. Signed informed consent
  2. Plaque psoriasis covering ³10% of total BSA
  3. Diagnosis of plaque psoriasis for at least 6 months
  4. A minimum PASI score of 12.0 at screening
  5. In the opinion of the investigator, candidate for systemic therapy for psoriasis
  6. Body weight of £120 kg
  7. 18 to 75 years old
  8. For women of childbearing potential and for men whose partner can become pregnant, use of an acceptable method of contraception to prevent pregnancy and agreement to continue to practice an acceptable method of contraception for the duration of their participation in the study (including the FU period).
  9. Willingness to hold sun exposure reasonably constant and to avoid use of tanning booths or other UV light sources during the study
  10. Willingness to enter Study

Exclusion Criteria:

  1. Guttate, erythrodermic, or pustular psoriasis as sole or predominant form of psoriasis
  2. History of severe allergic or anaphylactic reactions to humanised monoclonal antibodies or fusion proteins that contain an Ig Fc region
  3. Clinically significant psoriasis flare during screening or at the time of enrollment that would necessitate immediate relief for that patient
  4. History of or ongoing uncontrolled bacterial, viral, fungal, or atypical mycobacterial infection
  5. History of opportunistic infections (e.g., systemic fungal infections, parasites)
  6. Seropositivity for human immunodeficiency virus (HIV)

    • Patients will undergo mandatory testing at screening. Patients who are positive for HIV will be excluded.
  7. Pregnancy or lactation
  8. WBC count <4000/mL or >14,000/mL
  9. Patients with an history of clinically significant thrombocytopenia, bleeding disorder or a platelet count <100,000/mL
  10. Seropositivity for hepatitis B or C virus

    • Patients will undergo testing during screening. Patients who are positive for hepatitis B antigen or hepatitis C antibody will be excluded.
  11. Hepatic enzymes ³3 times the upper limit of normal
  12. History of active tuberculosis (TB) or currently undergoing treatment for TB

    • Chest X-ray within 3 months of Day 0 is required for all patients. Patients with a positive chest X-ray consistent with TB infection will be excluded.
  13. Presence of malignancy within the past 5 years, including lymphoproliferative disorders

    • Patients with a history of fully resolved basal cell or squamous cell skin cancer may be enrolled even if it is less than 5 years.
  14. Previous treatment with efalizumab (anti-CD11a)
  15. Diagnosis of hepatic cirrhosis, regardless of cause or severity
  16. Serum creatinine ³2 times the upper limit of normal
  17. Hospital admission for cardiac disease, stroke, or pulmonary disease within the last year
  18. History of substance abuse (e.g. narcotics, alcohol) within the last 5 years
  19. Any medical condition that, in the judgment of the investigator, would jeopardize the patient's safety following exposure to study drug

    Note: Restrictions and/or directions apply to the following treatments during specified time periods prior to initial study drug administration and during the study:

  20. Systemic therapy for psoriasis within 28 days prior to Study Day 0
  21. Systemic immunosuppressive drugs for other indications within 28 days prior to Study Day 0
  22. Topical therapies for psoriasis within 14 days prior to Study Day 0
  23. Live or killed virus or bacteria vaccines within 14 days prior to Study Day 0
  24. Other vaccines or allergy desensitization within 14 days prior to study Day 0
  25. Other experimental drugs or treatments within 28 days or five half lives, whichever is longer, prior to Day 0
  26. Use of b Blockers, ACE inhibitors, interferons, quinidine, antimalarial drugs, or lithium (if clinically indicated, such medications are allowed but the dosage should be held constant from Day -28 throughout the study)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00442650

Layout table for location information
Merck Serono Medical Information Office
Geneva, Switzerland
Sponsors and Collaborators
Merck KGaA, Darmstadt, Germany
Layout table for investigator information
Study Director: Daiana Licu, MD Merck Serono International SA
Publications of Results:
Layout table for additonal information Identifier: NCT00442650    
Other Study ID Numbers: 25030
First Posted: March 2, 2007    Key Record Dates
Last Update Posted: November 21, 2016
Last Verified: March 2009
Additional relevant MeSH terms:
Layout table for MeSH terms
Skin Diseases, Papulosquamous
Skin Diseases